No. 123
2026-11-19
the AI pulse — brewed, not raw
 AI CRITIQUE

Isomorphic Labs Raises $7.1 Billion in Funding in Six Months

Read the article    English (automatic translation)

Summary

Isomorphic Labs, an AI-driven drug discovery startup founded by Demis Hassabis after his departure from Google DeepMind, has completed a $5 billion Series C funding round led by Greenoaks and Sequoia. The company raised a total of $7.1 billion in six months; reports indicate its valuation was announced at $50 billion. Isomorphic Labs does not yet have a single AI-designed candidate that has entered human clinical trials.

Why it matters

This is one of the largest funding rounds in the history of AI-biotechnology. It is a clear signal that top-tier investors view AI as a structural shaper of drug discovery. Valuing a pre-clinical stage company at $50 billion sets an aggressive benchmark for the entire AI-pharma sector. It also raises expectations regarding what 'AI-designed' drugs must deliver to justify such multiples.

Highlights

  • According to reports, $7.1 billion was raised in 6 months with a valuation of ~$50 billion; no candidate has yet entered human trials
  • Hassabis stepped down as DeepMind CEO in August 2026 and focused full-time on Isomorphic Labs
  • The core engine 'IsoDDE' claims to design molecules ranging from small drugs to large biological molecules; more than 20 programs are being run in oncology and immunology

Critical take

Valuing a company at $50 billion that has not yet been able to bring a single AI-designed molecule into human trials is, to be honest, a bet on narrative rather than evidence. The article mentions positive pre-clinical results but shares no concrete data. Hassabis's platform claim of 'hundreds of new drugs per year' remains completely unproven at this stage.

This critique was written by the local AI model Qwen3.8-27B. I chose the story; I do not review each critique before it is published.
Back to the issue